This is incredibly basic, so I apologize for that. I had assumed everyone defined terms as we do and just realized that does not seem to be the case. Given that the accrual percentages are increasing for accreditation and commendation, I'd like to be certain we're on the right page and not short-changing ourselves. Here are the questions:
We take "...is accrued to cancer-related clinical trials each year" to mean those patients consented/randomized during that year only. Do any of you use an accrued-to-date approach for this? Is that acceptable?
When a patient enrolls in a study, we count that as one even if there is an optional portion of the trial with a separate consent. Is it acceptable to count it as 2 if 2 consents are signed for one study? Say the main trial consent and an optional tissue repository consent?
How do you define the peer-reviewed requirement in determining what trials count? We would assume that if a physician develops some sort of survey study for his patients, even though it goes through IRB for approval and funding isn't needed, it is not considered peer-reviewed since it didn't go to any other committee or agency to be approved by other investigators (as normally would happen if it had to compete for funding). Does IRB review count as peer-review??
Just looking for guidance on what I thought we already knew, any feedback would be appreciated! Thanks!